What are the critical factors that distinguish eltrombopag and romiplostim and are some patients more appropriately treated with one or the other?
Eltrombopag and romiplostim are new drugs that induce platelet-producing cells in the bone marrow to produce platelets. Eltrombopag is given orally, and romiplostim is given by subcutaneous injection. They both have low toxicity and have similar ability to raise platelet counts in patients with ITP over short and long periods. Some patients who either lack or lose response to one agent may respond to the other. http://www.promactacares.com/prescribing_information.pdf http://www.nplate.com/patient/pdf/nplate_pi.pdf Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S.Idiopathic thrombocytopenic purpura:current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4-13.
Related Questions
- What are the critical factors that distinguish eltrombopag and romiplostim and are some patients more appropriately treated with one or the other?
- Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?
- One of my ITP patients is developing hemolytic anemia and I suspect Evans syndrome. Would romiplostim or eltrombopag be appropriate?
